These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33806887)

  • 1. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution.
    Ding H; Xu T; Zhang J; Tolmachev V; Oroujeni M; Orlova A; Gräslund T; Vorobyeva A
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33806887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2.
    Xu T; Zhang J; Oroujeni M; Tretyakova MS; Bodenko V; Belousov MV; Orlova A; Tolmachev V; Vorobyeva A; Gräslund T
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model.
    Xu T; Ding H; Vorobyeva A; Oroujeni M; Orlova A; Tolmachev V; Gräslund T
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
    Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.
    Yin W; Xu T; Altai M; Oroujeni M; Zhang J; Vorobyeva A; Vorontsova O; Vtorushin SV; Tolmachev V; Gräslund T; Orlova A
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
    Rinne SS; Yin W; Borras AM; Abouzayed A; Leitao CD; Vorobyeva A; Löfblom J; Ståhl S; Orlova A; Gräslund T
    Biomedicines; 2022 May; 10(6):. PubMed ID: 35740315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
    Garousi J; Xu T; Liu Y; Vorontsova O; Hober S; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.
    Ding H; Altai M; Rinne SS; Vorobyeva A; Tolmachev V; Gräslund T; Orlova A
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31416167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein.
    Garousi J; Ding H; von Witting E; Xu T; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Gräslund T; Tolmachev V
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution.
    Ding H; Altai M; Yin W; Lindbo S; Liu H; Garousi J; Xu T; Orlova A; Tolmachev V; Hober S; Gräslund T
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32344762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 16. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
    Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
    Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by Z
    Siavoshinia L; Jamalan M; Zeinali M; Pourshohod A; Koushki M; Moradipoodeh B; Mohammadzadeh G
    Iran J Pathol; 2021; 16(2):109-118. PubMed ID: 33936221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.